Related references
Note: Only part of the references are listed.Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: A Case Report
Alfredo Adan et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2021)
Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis
Arash Maleki et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2021)
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
Nicolino Ruperto et al.
RHEUMATOLOGY (2021)
Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center
Luca Marelli et al.
FRONTIERS IN PEDIATRICS (2021)
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis
Elisabetta Miserocchi et al.
CLINICAL RHEUMATOLOGY (2020)
Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial
Athimalaipet Ramanan et al.
LANCET RHEUMATOLOGY (2020)
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond
Samendra Karkhur et al.
JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION (2019)
TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS- RELATED MACULAR EDEMA
Marina Mesquida et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis
Estefania Quesada-Masachs et al.
JOURNAL OF RHEUMATOLOGY (2017)
Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy A Multicenter Study of Twenty-Five Patients
Vanesa Calvo-Rio et al.
ARTHRITIS & RHEUMATOLOGY (2017)
How I treat juvenile idiopathic arthritis: A state of the art review
Rolando Cimaz et al.
AUTOIMMUNITY REVIEWS (2017)
Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis
Yasir Jamal Sepah et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis
Elisabetta Miserocchi et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
Christoph Tappeiner et al.
JOURNAL OF RHEUMATOLOGY (2016)
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Alan Kivitz et al.
ARTHRITIS CARE & RESEARCH (2014)
Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Protein-Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis
Hiroshi Haruta et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis
Takeru Yoshimura et al.
RHEUMATOLOGY (2009)
Serum cytokine levels in active uveitis and remission
M. Kramer et al.
CURRENT EYE RESEARCH (2007)
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop
DA Jabs et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2005)
Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: The Massachusetts eye & ear experience and review of previous studies
VL Perez et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2004)